Alembic Technologies, a pioneer in Causal AI for the enterprise, today announced it has secured $145 million in Series B and growth funding — a 15.7x increase in valuation over their Series A round.

Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical needSpringboard Health Angels, Pluton Asset Holding AG, Sintra Limited, ...